![Bärbel Rohrer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bärbel Rohrer active positions
Companies | Position | Start | End |
---|---|---|---|
Mitochem Therapeutics, Inc.
![]() Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | Director/Board Member | - | - |
Chief Tech/Sci/R&D Officer | - | - | |
Founder | - | - |
Career history of Bärbel Rohrer
Statistics
International
United States | 2 |
Operational
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Mitochem Therapeutics, Inc.
![]() Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | Health Technology |
- Stock Market
- Insiders
- Bärbel Rohrer
- Experience